Important Update About the Discontinuation of Commercialization of ABILIFY MYCITE® 

In October 2024, Otsuka Pharmaceutical Co., and Otsuka America Pharmaceutical, Inc. elected to discontinue commercialization of the ABILIFY MYCITE® System (aripiprazole tablet with sensor) in the U.S.

Our immediate priority is to provide a seamless transition for patients and healthcare professionals during this time.

ABILIFY MYCITE®, the world’s first U.S. FDA-approved digital medicine, launched in 2017 and represents an important milestone in Otsuka’s commitment to introducing innovative treatment options to people living with chronic, serious mental illness.  We have gained valuable insights and key learnings and will continue to monitor healthcare trends and use our deep knowledge and experience to develop new solutions.   
If you have any questions, please contact (1-800-441-6763).

November 2024          12US24EBC0038

 

Accept

Our Products

Below is a full list of the products marketed and commercialized in the US by OAPI that have been either developed, acquired, or in-licensed by Otsuka. Our product specialties include neuroscience, digital innovation, nephrology, oncology, and medical devices.

Prism-Image

Neuroscience

ABILIFY®
(aripiprazole)

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.abilify.com

ABILIFY ASIMTUFII®
(aripiprazole) for extended release injectable suspension

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.abilifyasimtufii.com

ABILIFY MAINTENA®
(aripiprazole) for
extended release
injectable suspension

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.abilifymaintena.com

NUEDEXTA®
(dextromethorphan HBr and quinidine sulfate) capsules

FULL PRESCRIBING INFORMATION

www.nuedexta.com

REXULTI®
(brexpiprazole)

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.rexulti.com

Digital Innovation

ABILIFY MYCITE®
(aripiprazole tablets with sensor)

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.abilifymycite.com

Nephrology

JYNARQUE®
(tolvaptan)

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.jynarque.com

SAMSCA®
(tolvaptan)

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

MEDICATION GUIDE
www.samsca.com

Oncology

IV BUSULFEX®
(busulfan)

FULL PRESCRIBING INFORMATION,
including BOXED WARNING

To report an adverse event or
product quality complaint,
please call 1-800-438-9927

To discuss a medical
inquiry, call 1-800-441-6763

To search for medical
information or submit a medical
inquiry, please click here

Discover additional resources for patients and caregivers.

PATIENT RESOURCES